Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
6 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia.
Clin Cancer Res. 2021 Jul 15;27(14):4003-4011. doi: 10.1158/1078-0432.CCR-20-3458. Epub 2021 Jun 8.
Clin Cancer Res. 2021.
PMID: 34103301
Free PMC article.
Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis.
Smith CC, Paguirigan A, Jeschke GR, Lin KC, Massi E, Tarver T, Chin CS, Asthana S, Olshen A, Travers KJ, Wang S, Levis MJ, Perl AE, Radich JP, Shah NP.
Smith CC, et al.
Blood. 2017 Jul 6;130(1):48-58. doi: 10.1182/blood-2016-04-711820. Epub 2017 May 10.
Blood. 2017.
PMID: 28490572
Free PMC article.
Clinical Trial.
Item in Clipboard
Fusion driven JMML: a novel CCDC88C-FLT3 fusion responsive to sorafenib identified by RNA sequencing.
Chao AK, Meyer JA, Lee AG, Hecht A, Tarver T, Van Ziffle J, Koegel AK, Golden C, Braun BS, Sweet-Cordero EA, Smith CC, Dvorak CC, Loh ML, Stieglitz E.
Chao AK, et al.
Leukemia. 2020 Feb;34(2):662-666. doi: 10.1038/s41375-019-0549-y. Epub 2019 Sep 12.
Leukemia. 2020.
PMID: 31511612
Free PMC article.
No abstract available.
Item in Clipboard
Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations.
Tarver TC, Hill JE, Rahmat L, Perl AE, Bahceci E, Mori K, Smith CC.
Tarver TC, et al.
Blood Adv. 2020 Feb 11;4(3):514-524. doi: 10.1182/bloodadvances.2019000919.
Blood Adv. 2020.
PMID: 32040554
Free PMC article.
Item in Clipboard
The Irreversible FLT3 Inhibitor FF-10101 Is Active Against a Diversity of FLT3 Inhibitor Resistance Mechanisms.
Ferng TT, Terada D, Ando M, Tarver TC, Chaudhary F, Lin KC, Logan AC, Smith CC.
Ferng TT, et al. Among authors: tarver tc.
Mol Cancer Ther. 2022 May 4;21(5):844-854. doi: 10.1158/1535-7163.MCT-21-0317.
Mol Cancer Ther. 2022.
PMID: 35395091
Free PMC article.
Item in Clipboard
Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AML.
Popescu B, Stahlhut C, Tarver TC, Wishner S, Lee BJ, Peretz CAC, Luck C, Phojanakong P, Camara Serrano JA, Hongo H, Rivera JM, Xirenayi S, Chukinas JA, Steri V, Tasian SK, Stieglitz E, Smith CC.
Popescu B, et al. Among authors: tarver tc.
Cell Rep Med. 2023 Nov 21;4(11):101290. doi: 10.1016/j.xcrm.2023.101290.
Cell Rep Med. 2023.
PMID: 37992684
Free PMC article.
Item in Clipboard
Cite
Cite